AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs
AbbVie shares fell 1.1% to $214.35 after its blood cancer drug epcoritamab failed to show a clear overall-survival benefit in a late-stage trial. U.S. stock and bond markets were closed Monday for Martin Luther King Jr. Day. Investors are awaiting AbbVie’s Feb. 4 earnings for updated 2026 guidance.